Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free SCLX Stock Alerts

Scilex (SCLX) Competitors

Scilex logo
$5.04 -0.33 (-6.15%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$5.10 +0.06 (+1.19%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SCLX vs. LFCR, MENS, IMUX, NRXP, and LENZ

Should you buy Scilex stock or one of its competitors? Scilex's main competitors and comparable companies include Lifecore Biomedical (LFCR), Jyong Biotech (MENS), Immunic (IMUX), NRx Pharmaceuticals (NRXP), and LENZ Therapeutics (LENZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scilex compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 4.5% of Scilex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Lifecore Biomedical had 1 more articles in the media than Scilex. MarketBeat recorded 1 mentions for Lifecore Biomedical and 0 mentions for Scilex. Lifecore Biomedical's average media sentiment score of 0.21 beat Scilex's score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company Overall Sentiment
Lifecore Biomedical Neutral
Scilex Neutral

Lifecore Biomedical has higher revenue and earnings than Scilex. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifecore Biomedical$128.87M1.31-$40.50M-$1.07N/A
Scilex$30.25M1.41-$358.73M-$49.70N/A

Lifecore Biomedical has a net margin of -29.93% compared to Scilex's net margin of -1,414.57%.

Company Net Margins Return on Equity Return on Assets
Lifecore Biomedical-29.93% N/A -16.16%
Scilex -1,414.57%N/A -147.00%

Lifecore Biomedical has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Scilex has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

Lifecore Biomedical currently has a consensus price target of $6.50, suggesting a potential upside of 45.74%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, research analysts clearly believe Lifecore Biomedical is more favorable than Scilex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifecore Biomedical
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Scilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Lifecore Biomedical beats Scilex on 12 of the 15 factors compared between the two stocks.

How does Scilex compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

69.7% of Scilex shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Jyong Biotech had 1 more articles in the media than Scilex. MarketBeat recorded 1 mentions for Jyong Biotech and 0 mentions for Scilex. Jyong Biotech's average media sentiment score of 0.75 beat Scilex's score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Jyong Biotech Positive
Scilex Neutral

Jyong Biotech has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market. Comparatively, Scilex has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Scilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Jyong Biotech has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%.

Company Net Margins Return on Equity Return on Assets
Jyong BiotechN/A N/A N/A
Scilex -1,414.57%N/A -147.00%

Jyong Biotech has higher earnings, but lower revenue than Scilex.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jyong BiotechN/AN/A-$4.67MN/AN/A
Scilex$30.25M1.41-$358.73M-$49.70N/A

Summary

Jyong Biotech beats Scilex on 6 of the 9 factors compared between the two stocks.

How does Scilex compare to Immunic?

Immunic (NASDAQ:IMUX) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Immunic has higher earnings, but lower revenue than Scilex. Immunic is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunicN/AN/A-$97.17M-$4.38N/A
Scilex$30.25M1.41-$358.73M-$49.70N/A

In the previous week, Immunic had 2 more articles in the media than Scilex. MarketBeat recorded 2 mentions for Immunic and 0 mentions for Scilex. Immunic's average media sentiment score of 0.46 beat Scilex's score of 0.00 indicating that Immunic is being referred to more favorably in the media.

Company Overall Sentiment
Immunic Neutral
Scilex Neutral

Immunic presently has a consensus price target of $47.25, suggesting a potential upside of 344.25%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Scilex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunic
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
3 Strong Buy rating(s)
3.00
Scilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Immunic has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, Scilex has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Immunic has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Immunic's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunicN/A -157.89% -107.88%
Scilex -1,414.57%N/A -147.00%

51.8% of Immunic shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 5.5% of Immunic shares are owned by company insiders. Comparatively, 4.5% of Scilex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Immunic beats Scilex on 11 of the 16 factors compared between the two stocks.

How does Scilex compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NRx Pharmaceuticals has higher earnings, but lower revenue than Scilex. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$1.23M116.87-$28.62M-$0.55N/A
Scilex$30.25M1.41-$358.73M-$49.70N/A

NRx Pharmaceuticals has a net margin of -691.81% compared to Scilex's net margin of -1,414.57%.

Company Net Margins Return on Equity Return on Assets
NRx Pharmaceuticals-691.81% N/A -63.92%
Scilex -1,414.57%N/A -147.00%

NRx Pharmaceuticals currently has a consensus target price of $34.50, suggesting a potential upside of 939.16%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Scilex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.43
Scilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Scilex has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 10 more articles in the media than Scilex. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 0 mentions for Scilex. NRx Pharmaceuticals' average media sentiment score of 0.66 beat Scilex's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
NRx Pharmaceuticals Positive
Scilex Neutral

Summary

NRx Pharmaceuticals beats Scilex on 12 of the 15 factors compared between the two stocks.

How does Scilex compare to LENZ Therapeutics?

Scilex (NASDAQ:SCLX) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

LENZ Therapeutics has a consensus price target of $28.80, suggesting a potential upside of 607.62%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Scilex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Scilex has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

In the previous week, LENZ Therapeutics had 3 more articles in the media than Scilex. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Scilex. LENZ Therapeutics' average media sentiment score of 0.36 beat Scilex's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Scilex Neutral
LENZ Therapeutics Neutral

69.7% of Scilex shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 4.5% of Scilex shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LENZ Therapeutics has a net margin of -586.74% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scilex-1,414.57% N/A -147.00%
LENZ Therapeutics -586.74%-53.39%-49.14%

LENZ Therapeutics has lower revenue, but higher earnings than Scilex. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scilex$30.25M1.41-$358.73M-$49.70N/A
LENZ Therapeutics$19.09M6.70-$82.13M-$4.09N/A

Summary

LENZ Therapeutics beats Scilex on 11 of the 16 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLX vs. The Competition

Export
MetricScilexPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$42.80M$12.47B$7.24B$13.19B
Dividend YieldN/A2.64%2.57%12.81%
P/E Ratio-0.10792.21274.9325.38
Price / Sales1.41753.62646.0189.45
Price / CashN/A86.3676.2551.42
Price / Book-0.2010.5310.466.33
Net Income-$358.73M$2.82B$3.49B$358.33M
7 Day Performance0.60%1.69%0.59%1.12%
1 Month Performance-10.80%0.83%-2.01%-2.67%
1 Year Performance-82.67%3.90%18.09%6.01%

Scilex Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLX
Scilex
0.2372 of 5 stars		$5.04
-6.1%		N/A-80.4%$42.80M$30.25MN/A34
LFCR
Lifecore Biomedical
1.3295 of 5 stars		$4.21
-0.9%		$6.50
+54.4%		-43.8%$159.36M$128.87MN/A690
MENS
Jyong Biotech
N/A$2.15
+3.1%		N/A-96.0%$158.14MN/AN/A31
IMUX
Immunic
2.7851 of 5 stars		$11.04
-1.7%		$47.25
+328.2%		+26.6%$151.99MN/AN/A70
NRXP
NRx Pharmaceuticals
1.9621 of 5 stars		$3.39
-3.0%		$34.50
+919.2%		+11.4%$146.77M$3.39MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCLX) was last updated on 9/19/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel